Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Ann Oncol
; 30(4): 612-620, 2019 04 01.
Article
in En
| MEDLINE
| ID: mdl-30657848
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hodgkin Disease
/
Antineoplastic Combined Chemotherapy Protocols
/
Salvage Therapy
/
Chemotherapy-Induced Febrile Neutropenia
/
Brentuximab Vedotin
/
Neoplasm Recurrence, Local
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2019
Type:
Article